PGR and cancer: Only ER/PR/HER2 status was significantly associated with death in this model; patients with triple-negative disease experienced 2.27 (95% CI: 1.33, 3.88) times the hazard of death compared to patients with HER2-negative, ER- and/or PR-positive cancer.